Dear Advocates,

Genentech is preparing for World Hemophilia Day (WHD) on Monday, April 17th. This year's theme, ‘Hear their Voices,’ brings attention to the millions of women and girls who live with a bleeding disorder or have someone in their lives who does.
We are happy to share the following information/resources available now on our global hemophilia hub

•       An interview with 
Dr Danielle Nance, who shared her personal experience not only as a woman living with hemophilia but also the mother of a son with hemophilia A as well as a treating physician of people with bleeding disorders.

•       The Team Clotting animated video series, a 2-part animated series which gives viewers an overview of how hemophilia A impacts the clotting cascade as well as the impact of inhibitors
To share the Team Clotting animations, copy and paste this link into an email/website page or social media post: http://bit.ly/teamclotting

To share Dr. Nance’s interview, copy and paste this link into an email/website page or social media post: http://bit.ly/drnance

And finally, as a reminder, we’ve just launched a fun new way for the community to engage with the clotting cascade via an interactive game called Factor Fusion. To share Factor Fusion, copy and paste this link http://bit.ly/FactorFusion.

As always, happy to hear your feedback or answer any questions you may have!

Our best ... Sonali Chopra & Lauren Davis

********************************************************************************

Genentech Alliance and Advocacy Relations, Hemophilia

Genentech, a member of the Roche Group, this evening announced positive interim results from the phase III HAVEN 2 study evaluating

emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII.

-
Emicizumab prophylaxis reduced the number of bleeds in children with hemophilia A and inhibitors to factor VIII.
- These results build upon data reported from the phase III HAVEN 1 study.

The press release is attached below:

Genentech, a member of the Roche Group, this evening announced positive interim results from the phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A and inhibitors to factor VIII.

- Emicizumab prophylaxis reduced the number of bleeds in children with hemophilia A and inhibitors to factor VIII.
- These results build upon data reported from the phase III HAVEN 1 study.

The press release is attached below:

 

Emicizumab prophylaxis Press Release

********************************************************************************

 

"Patient Puppet"

We donated a "Patient Puppet" to the Hemophilia Treatment Center in Long Island Jewish Medical Center. The patient puppet, has a port, a PIC line, a bruise site, and a Hemophiliac knee joint, to educate and demonstrate to kids about Hemophilia.

********************************************************************************

 

 

700 Facebook Likes !!!

Please Share our FaceBook page with your friends and family.